Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
preEMBER: imlunestrant in premenopausal ER-positive, HER2-negative early breast cancer
2025-523258-15-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of imlunestrant in breast cancer (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Change from baseline in Ki-67 expression and Rate of symptomatic ovarian cysts. Planned start Aug 2026; status: authorised.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-523258-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523258-15-00.